Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Gains from Sales and Divestitures (2018 - 2025)

Nephros' quarterly Gains from Sales and Divestitures came in at $70708.0 in Q4 2025, up 67.69% year-on-year from $42167.0 in Q4 2024, and down 56.04% quarter-over-quarter from $160843.0 in Q3 2025.

Nephros has reported Gains from Sales and Divestitures for 8 years, with the latest figure at $70708.0 in Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 67.69% year-over-year to $70708.0; the trailing twelve-month figure through Dec 2025 stood at $70708.0 (up 67.69% YoY), and the FY2025 full-year result was $70708.0, up 67.69% from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 stood at $70708.0, down from $160843.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $187503.0 in Q4 2023, with the low at $23781.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 5 years is $102682.8, with a median of $108161.0 recorded in 2025.
  • Year-over-year, Gains from Sales and Divestitures tumbled 99.96% in 2021 and soared 319.17% in 2023.
  • Tracing NEPH's Gains from Sales and Divestitures over 5 years: stood at $23781.0 in 2021, then surged by 88.1% to $44732.0 in 2022, then soared by 319.17% to $187503.0 in 2023, then plunged by 77.51% to $42167.0 in 2024, then jumped by 67.69% to $70708.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $70708.0 (Q4 2025), $160843.0 (Q3 2025), and $146114.0 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Nephros 38.93 Mn 34.91 Mn 2.99 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 70,708.00
Dec 31, 2025 70,708.00
Sep 30, 2025 160,843.00
Sep 30, 2025 160,843.00
Jun 30, 2025 146,114.00
Jun 30, 2025 146,114.00
Mar 31, 2025 145,614.00
Mar 31, 2025 145,614.00
Dec 31, 2024 42,167.00
Dec 31, 2024 42,167.00
Dec 31, 2023 187,503.00
Dec 31, 2023 187,503.00
Dec 31, 2022 44,732.00
Dec 31, 2022 44,732.00
Dec 31, 2021 23,781.00
Dec 31, 2021 23,781.00
Dec 31, 2020 55.11 Mn
Dec 31, 2020 55.11 Mn
Dec 31, 2019 45,160.00
Dec 31, 2019 45,160.00
Dec 31, 2018 83,725.00
Dec 31, 2018 83,725.00